CCL Nov 2017 - The Cancer Letter

Subscription Change

This change will be effective immediately and your card will be charged a prorated amount based on your existing subscription level.

OK Cancel

Request Cancellation

Renew today!

Your subscription has lapsed. Subscribe today to access this content.

SUBSCRIBE NOW

Subscriber content

Log in or subscribe to access The Cancer Letter.

LOGIN SUBSCRIBE NOW

SEARCH DATE

SEARCH TEXT

Cancel

OK

Cancel

OK

Delete Account

Are you sure you want to delete your account? This will erase all of your account data from the site. To delete your account enter your password below

CD22 CAR-T therapy shows results in leukemia study

Mount Sinai researchers develop first mathematical model for predicting patient response to immunotherapy

Phase III study shows Tecentriq and Avastin plus chemo reduced risk of disease progression or death in advanced lung cancer

Novartis reports positive results from phase III trial of Kisqali for advanced or metastatic breast cancer

Clinical data for CXCR4 inhibitor, Inlyta showa 29% ORR in clear cell renal cell carcinoma

Ziopharm announces positive updated results of Ad-RTS-hIL-12 study in brain cancer

NCI CTEP-Approved Trials for November

FDA approves adjuvant indication for Sutent in renal cell carcinoma

Recent Issues

Renew today!

Subscriber content

Login